Endometriosis affects an estimated 1 in 10 women in the reproductive age group of 15-49 years.
Among these therapies, Elagolix, a first-in-class GnRH receptor antagonist, is closest to market.
The report comprises of key players profiles namely consignment, price, revenue, profit interview records and sources of distribution. It helps clients get a better analysis of their competitors. In addition, it encompasses the regions and countries across the world and depicts the regional outlook, market size, volume, value and price data.
The Endometriosis Drugs market was valued at xxx million USD with a CAGR xx% from 2015-2019. Subsequently, it will touch xxx million USD in 2020 with a CAGR xx % from 2020 to 2025.
Global market, the following companies are covered:
AbbVie
Astellas Pharma
AstraZeneca
Debiopharm Group
Evotec AG
Kissei Pharmaceutical
Neurocrine Biosciences
ObsEva
Pfizer
Repros Therapeutics
Roivant Sciences GmbH
Takeda Pharmaceutical Company Limited
ValiRx
Market Segment by Product Type
Hormonal Therapy
Add-back Medication
Progestogens
Chinese Herbs
Market Segment by Application
Hospitals
Clinics
Research Institutes
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Endometriosis Drugs market for the forecast period 2020 - 2025?
• What are the driving forces in the Endometriosis Drugs market for the forecast period 2020 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Endometriosis Drugs industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?